Non-Opioid Pain Management: Complete Attorney Guide

James Wong — Founder & CEO, LienScripts | March 26, 2026 | 8 min read

Modern pain management in personal injury cases increasingly relies on non-opioid alternatives — NSAIDs, gabapentinoids, SNRIs, topical agents, Journavx, and CGRP inhibitors. Understanding these drug classes helps attorneys explain pharmacy liens and build stronger demand packages.

Non-Opioid Pain Management: Complete Attorney Guide

Non-opioid pain management has become the standard of care in personal injury treatment, replacing the opioid-first approach that dominated for decades. Modern PI patients receive prescriptions for gabapentinoids, SNRIs, topical agents, CGRP inhibitors, and novel analgesics like Journavx (suzetrigine) — drugs that target specific pain mechanisms without the addiction risk, cognitive impairment, and regulatory scrutiny associated with opioids.

• NSAIDs address inflammation but are insufficient for neuropathic or complex pain
• Gabapentinoids (gabapentin, pregabalin) are first-line for nerve injury pain
• SNRIs (duloxetine, venlafaxine) treat pain with a co-existing depression/anxiety component
• Topical agents (lidocaine, diclofenac, compounded creams) provide targeted relief without systemic side effects
• Journavx (suzetrigine) is the first selective Nav1.8 inhibitor — a new drug class for acute pain
• CGRP inhibitors (Qulipta, Nurtec, Aimovig) target post-traumatic migraine at the molecular level
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages

Why Non-Opioid Treatment Supports Higher Settlement Values

A medication regimen that avoids opioids is not a sign of less severe injury — it reflects more sophisticated, targeted treatment that addresses specific pain mechanisms.

According to James Wong, PharmD, founder of LienScripts, "When a PI patient is prescribed four different non-opioid medications instead of one opioid, it means the treating physician identified four distinct pain mechanisms — neuropathic, inflammatory, muscular, and migrainous — each requiring a targeted drug. That's evidence of injury complexity, not over-treatment."

[!KEY] Multiple non-opioid medications on a pharmacy lien document multiple distinct pain mechanisms — each corresponding to a specific type of tissue or nerve injury. This is stronger evidence of injury complexity than a single opioid prescription that masks all pain indiscriminately.

NSAIDs: The Foundation of Anti-Inflammatory Treatment

Common PI prescriptions: Meloxicam, celecoxib (Celebrex), naproxen, diclofenac

NSAIDs reduce inflammation at the injury site by inhibiting cyclooxygenase (COX) enzymes. They are typically the first prescribed medication after an injury and may continue for weeks to months.

Evidentiary value: Ongoing NSAID prescriptions document persistent inflammation. A switch from OTC ibuprofen to prescription celecoxib documents that the inflammatory component is significant enough to require stronger, targeted therapy.

Why prescription NSAIDs appear on liens: Prescription-strength NSAIDs (meloxicam 15mg, celecoxib 200mg) are stronger than OTC options and require physician monitoring for GI and cardiovascular risks — another indicator of injury severity requiring medical management.

Gabapentinoids: First-Line Neuropathic Pain Treatment

Common PI prescriptions: Gabapentin (Neurontin), pregabalin (Lyrica)

Gabapentinoids calm overactive nerve signals by binding to voltage-gated calcium channels. They are the standard treatment for radiculopathy, herniated disc nerve compression, and traumatic neuropathy.

Evidentiary value: A gabapentinoid prescription documents nerve injury — a more serious diagnosis than soft tissue inflammation alone. Dose escalation over time documents persistent or worsening nerve damage.

SNRIs: Dual-Action Pain and Mood Treatment

Common PI prescriptions: Duloxetine (Cymbalta), venlafaxine (Effexor XR), milnacipran (Savella)

SNRIs increase serotonin and norepinephrine levels in the central nervous system. Both neurotransmitters play roles in pain modulation — the descending pain inhibitory pathway uses serotonin and norepinephrine to suppress pain signals at the spinal cord level.

Why they appear on PI pharmacy liens: SNRIs treat both the pain itself (through descending inhibition) and the depression/anxiety that commonly accompanies chronic pain after injury. Duloxetine is FDA-approved for chronic musculoskeletal pain, diabetic neuropathy, and fibromyalgia — all conditions that can result from PI accidents.

[!TIP] When duloxetine appears on a pharmacy lien, it may be prescribed for pain, for co-existing depression, or for both simultaneously. MERIT documentation from LienScripts clarifies the clinical indication, preventing adjusters from dismissing it as "just an antidepressant."

Evidentiary value: An SNRI prescription documents that the injury has progressed beyond simple tissue damage to affect the patient's neurological pain processing system — a finding consistent with chronic pain syndrome.

Topical Agents: Targeted Pain Without Systemic Effects

Common PI prescriptions: Lidocaine patches (Lidoderm), diclofenac gel (Voltaren), compounded topical creams (ketamine/gabapentin/lidocaine combinations)

Topical agents deliver medication directly to the pain site, avoiding systemic side effects. They are particularly useful for patients who cannot tolerate oral medications or who have localized pain.

Evidentiary value: Compounded topical prescriptions document that the treating physician determined standard oral medications were insufficient and prescribed a custom formulation tailored to the patient's specific pain characteristics.

Journavx (Suzetrigine): The Newest Non-Opioid

Generic name: Suzetrigine Brand name: Journavx Mechanism: Selective Nav1.8 sodium channel inhibitor

Journavx is the first drug in an entirely new class — it selectively blocks Nav1.8 sodium channels, which are found primarily on pain-sensing neurons. This provides analgesic effect comparable to opioids without affecting the brain's reward system, eliminating addiction risk.

Why it matters for PI cases: When a physician prescribes Journavx, they are documenting that the patient's acute pain is severe enough to warrant a medication with opioid-level efficacy — but choosing a non-addictive alternative. This prescription choice documents both pain severity and responsible prescribing.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Journavx on a pharmacy lien tells a specific story: the pain is severe enough for an opioid-class analgesic, but the physician chose the newest, safest option. That's a strong piece of evidence for the demand package."

CGRP Inhibitors: Post-Traumatic Migraine Treatment

Common PI prescriptions: Atogepant (Qulipta), rimegepant (Nurtec ODT), erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality)

CGRP (calcitonin gene-related peptide) inhibitors target the specific molecular pathway responsible for migraine. They represent the most targeted migraine treatment available — developed specifically for migraine rather than repurposed from other conditions.

Why they appear on PI pharmacy liens: Post-traumatic migraine is common after TBI, concussion, whiplash, and cervical spine injuries. CGRP inhibitors document that the patient's post-traumatic headaches are severe and frequent enough to require the most advanced available treatment.

[!KEY] CGRP inhibitors are among the most expensive medications on PI pharmacy liens, but their presence documents a specific, objectively treatable neurological condition caused by the accident. The medication cost reflects the clinical severity of the post-traumatic migraine.

Evidentiary value: A CGRP inhibitor prescription distinguishes post-traumatic migraine from ordinary headache — it documents a specific neurological diagnosis that requires specialized treatment.

Building the Non-Opioid Narrative in Demand Packages

When preparing a demand package that includes non-opioid medications on a pharmacy lien, frame the medication list as evidence of injury complexity:

1. Each drug class = a distinct injury mechanism. An NSAID + gabapentinoid + SNRI regimen documents inflammatory, neuropathic, and central sensitization components.
2. Non-opioid choice = physician sophistication. Targeted treatment shows the physician identified specific pain mechanisms rather than prescribing a blanket opioid.
3. Treatment duration = injury chronicity. Months of non-opioid prescriptions document that the injury has not resolved with time alone.
4. Treatment escalation = severity progression. Adding medications over time documents worsening or resistant symptoms.

LienScripts MERIT documentation explains each medication's role in the treatment regimen, tying every prescription to the accident-related diagnosis and clinical rationale.

Contact LienScripts to learn how MERIT documentation supports non-opioid medication narratives in your demand packages.

Related Resources

• Anticonvulsant Medications in PI Cases
• Pain Management After a Car Accident
• Combination Drug Therapy in Personal Injury